| Somatotropin deficiency
Ngenla vs Nutropin AQ
Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.Deep comparison between: Ngenla vs Nutropin Aq Nuspin 10 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNutropin Aq Nuspin 10 has a higher rate of injection site reactions vs Ngenla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nutropin Aq Nuspin 10 but not Ngenla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ngenla
Nutropin Aq Nuspin 10
At A Glance
SC injection
Once weekly
Growth hormone analog
SC injection
Daily
Recombinant human growth hormone
Indications
- Somatotropin deficiency
- Somatotropin deficiency
- Turner Syndrome
- Chronic Kidney Diseases
Dosing
Somatotropin deficiency 0.66 mg/kg based on actual body weight administered SC once weekly; individualize dosage based on growth response. When switching from daily growth hormone, initiate NGENLA on the day following the last daily injection.
Somatotropin deficiency (pediatric) Up to 0.3 mg/kg/week divided into daily SC injections; pubertal patients may use up to 0.7 mg/kg/week divided daily.
Somatotropin deficiency (adult) Weight-based: starting dose up to 0.006 mg/kg/day SC, max 0.025 mg/kg/day (age <=35 years) or 0.0125 mg/kg/day (age >35 years); or non-weight-based: starting dose approximately 0.2 mg/day SC with gradual titration every 1-2 months.
Chronic Kidney Diseases Up to 0.35 mg/kg/week divided into daily SC injections; therapy may continue until renal transplantation.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses 3 to 7 times per week by SC injection.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somatrogon-ghla or any excipient in NGENLA
- Closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome in children with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphysis (for growth promotion in pediatric patients)
Adverse Reactions
Most common (>=5%) Injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, oropharyngeal pain
Serious Increased mortality in acute critical illness, severe hypersensitivity, increased risk of neoplasm, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in pediatric patients with Prader-Willi syndrome
Postmarketing Osteonecrosis in pediatric patients
Most common Edema or peripheral edema (adults with GHD), arthralgias (adults with GHD), otitis media and ear disorders (Turner syndrome), injection site discomfort (pediatric GHD)
Serious Intracranial hypertension, glucose intolerance, slipped capital femoral epiphysis, scoliosis progression, leukemia, pancreatitis, severe hypersensitivity reactions, hypothyroidism, hypoadrenalism, lipoatrophy
Postmarketing Anaphylaxis, angioedema, leukemia, gynecomastia (children), pancreatitis, slipped capital femoral epiphysis, osteonecrosis
Pharmacology
Somatrogon-ghla is a human growth hormone analog that binds to the GH receptor and activates the STAT5b signaling pathway, increasing serum IGF-1 concentrations and stimulating linear growth and metabolic changes in pediatric patients with growth hormone deficiency.
Somatropin is a recombinant human growth hormone that binds to dimeric GH receptors on target cell membranes, triggering intracellular signal transduction; pharmacodynamic effects include skeletal growth and protein synthesis mediated via IGF-1, as well as direct effects such as lipolysis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ngenla
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Nutropin Aq Nuspin 10
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Ngenla
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Nutropin Aq Nuspin 10
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ngenla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Nutropin Aq Nuspin 10
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Ngenla Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Nutropin Aq Nuspin 10.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NgenlaView full Ngenla profile
Nutropin Aq Nuspin 10View full Nutropin Aq Nuspin 10 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.